171 related articles for article (PubMed ID: 29696406)
1. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer.
Akutagawa T; Aoki S; Yamamoto-Rikitake M; Iwakiri R; Fujimoto K; Toda S
Gastric Cancer; 2018 Nov; 21(6):946-955. PubMed ID: 29696406
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
3. Interaction between adipose tissue stromal cells and gastric cancer cells in vitro.
Nomoto-Kojima N; Aoki S; Uchihashi K; Matsunobu A; Koike E; Ootani A; Yonemitsu N; Fujimoto K; Toda S
Cell Tissue Res; 2011 May; 344(2):287-98. PubMed ID: 21384185
[TBL] [Abstract][Full Text] [Related]
4. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
5. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
[TBL] [Abstract][Full Text] [Related]
7. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
Noyan S; Gurdal H; Gur Dedeoglu B
PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
[TBL] [Abstract][Full Text] [Related]
8. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
Liu N; Zhu M; Linhai Y; Song Y; Gui X; Tan G; Li J; Liu Y; Deng Z; Chen X; Wang J; Jia L; He X; Wang X; Lin S
Oncol Rep; 2018 Nov; 40(5):2997-3005. PubMed ID: 30226606
[TBL] [Abstract][Full Text] [Related]
9. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
10. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
11. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
[TBL] [Abstract][Full Text] [Related]
13. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
14. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
[TBL] [Abstract][Full Text] [Related]
15. HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab.
Bie L; Luo S; Li D; Wei Y; Mu Y; Chen X; Wang S; Guo P; Lu X
Curr Cancer Drug Targets; 2020; 20(9):700-709. PubMed ID: 32364078
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
17. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity.
Cardoso AP; Pinto ML; Pinto AT; Oliveira MI; Pinto MT; Gonçalves R; Relvas JB; Figueiredo C; Seruca R; Mantovani A; Mareel M; Barbosa MA; Oliveira MJ
Oncogene; 2014 Apr; 33(16):2123-33. PubMed ID: 23644655
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
[TBL] [Abstract][Full Text] [Related]
19. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]